Project Grant R43AR082756
Award Date
9/5/23
Completion Date
8/31/24
Dollars Obligated
$296K
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine to develop and characterize cell-penetrating botulinum protease variants that can inhibit neurotransmitter release and immune cell signaling in skin. The goal is to create a new topical therapeutic strategy to regulate inflammation in skin diseases like psoriasis and atopic...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
This federal Project Grant award, with ID R01AR084848, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant is funding research focused on understanding the cellular and molecular mechanisms of interleukin-17A (IL-17A) in the pathogenesis of psoriatic arthritis. The research aims to develop a novel animal model of IL-17A gene transfer to study the early...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides funding of $613,036 to Fibrobiologics LLC for the development of a novel peptide-based therapeutic agent called M10 as a treatment for skin fibrosis associated with systemic sclerosis (scleroderma). The research aims to determine the antifibrotic activity of M10 in primary skin...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is supporting research to investigate the impact of dietary lipid components on phototherapy treatments for inflammatory skin conditions. The $673,729 award, effective from April 10, 2025 to March 31, 2030, is being provided to the University of Pittsburgh to: Define the impact of dietary...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding the discovery and development of novel small molecule therapeutics for the treatment of vitiligo. The key products and services being delivered include: Investigating a lead compound, COB-187, to determine its ability to attenuate interferon-gamma induced cytokine expression in human...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $383,570 to Temple University to conduct research on interleukin-36 (IL-36) cytokine activation and inactivation mechanisms. The project aims to improve understanding of IL-36 functions and their role in inflammatory conditions, such as atopic dermatitis, psoriasis, and skin infections,...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) totals $1,538,124 and aims to develop a novel treatment for hypertrophic scarring. The key products and services to be delivered include: Mechanism-of-action studies to understand how the therapeutic protein relaxin-2 can reduce fibrosis and excessive scarring in a 3D skin model and patient...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of B cells in the pathogenesis of psoriatic arthritis (PsA). The $735,460 award to Vanderbilt University Medical Center will leverage a mouse model of PsA to demonstrate how decreases in anti-inflammatory IL-10-producing B regulatory (Breg) cells and increases in...